Profound symptomatic bradycardia associated with combined mibefradil and B‐blocker therapy
- 1 October 1998
- journal article
- notable cases
- Published by AMPCo in The Medical Journal of Australia
- Vol. 169 (8) , 425-427
- https://doi.org/10.5694/j.1326-5377.1998.tb126834.x
Abstract
We report two cases where the addition of mibefradil to long term {3‐blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.Keywords
This publication has 6 references indexed in Scilit:
- Life-Threatening Interaction of Mibefradil and β-Blockers With Dihydropyridine Calcium Channel BlockersJAMA, 1998
- Adding the new calcium antagonist mibefradil to patients receiving long-term β-blocker therapy results in improved antianginal and antiischemic efficacyAmerican Heart Journal, 1998
- Mibefradil: A Selective T-Type Calcium AntagonistThe American Journal of Cardiology, 1997
- Pharmacologic and Pharmacokinetic Profile of Mibefradil, a T- and L-type Calcium Channel AntagonistThe American Journal of Cardiology, 1997
- Safety of Mibefradil, a New Once-a-Day, Selective T-Type Calcium Channel AntagonistThe American Journal of Cardiology, 1997
- Predictable clinical effects in the treatment of hypertension and chronic, stable angina pectorisJournal Of Hypertension, 1997